Examination of participants prior to chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples

Examination of participants immediately after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples

Examination of participants one year after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples

Breast Neoplasms

Endothelial Dysfunction

Cardiovascular Disease

Metabolic Syndrome

To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.

Venous occlusion plethysmography

Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.
Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously.

SphygmoCor

24hour blood pressure

Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).

DEXA scan

Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).
Further more urine samples to determine possible systemic impact of cardiovascular disease.
We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.
Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen.

Laboratory blood samples

Aarhus University Hospital

Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium

P-Kolesterol, P-Kolesterol HDL, P-Kolesterol LDL, P-Triglyceride, P-Glukose, P-Progesteron, P-Testosteron, P-Von Willebrand-faktor, P-Natrium, P-Kalium, P-Kreatinin and P-Østradiol.

The SCORE-system is a well- established and validated method using age, gender, smoking status, systolic blood pressure and plasma cholesterol for risk stratification.

University of Aarhus

Danish Cancer Society

Women who were curatively treated with chemo- and/or radiotherapy for breast cancer

Women matched on age and general practitioner with the breast cancer patients

EDTA-plasma, Heparin-Lithium plasma, Serum, Frozen whole blood

University Medical Center Groningen (UMCG)

Breast Cancer Long-term Outcome of Cardiac Dysfunction

Study of the Cardiovascular and Psychosocial Effects of the Treatment of Breast Cancer With Chemotherapy and/or Radiotherapy

systolic and diastolic parameters at time of inclusion

Plasma EDTA, lithium-heparin plasma and serum are stored at -80 freezer at the the time of inclusion. Determination of biomarkers will take place at the end of the study period Whole blood is frozen for DNA analysis at time of inclusion.

Questionnaires (CVRM, HADS and MFI-20), a short physical examination and a electrocardiography at time of inclusion

Dr. A.J. Berendsen

University Medical Center Groningen

Fenretinide (4-HPR) plus Intravenous Safingol

Solid Tumor

A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.
Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects.

University of Texas Southwestern

Joe Arrington Cancer Center/Covenant Children's Hospital

University Medical Center

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies

The primary outcome mesure of this study is to determine the maximum tolerated dose (MTD) of an intravenous (emulsion) safingol when administered as a continuous intravenous (c.i.v.) infusion for two days, once every 3 weeks, in combination with fenretinide (4-HPR) intravenous emulsion administered as a continuous intravenous infusion for five days, once every 3 weeks.

cardiotoxicity/triglyceride

Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium

Breast Cancer Long-term Outcome of Cardiac Dysfunction

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

The most complete medicinal herbs database backed by science